IBTimes -
31 Jul 2014 20:34
The Google (NASDAQ:GOOG)-backed home genetic testing company 23andMe may be having a second life thanks to government interest in the genetic data collected by a product the FDA said was in violation of marketing regulations.
Share this Article
Comment on this Article
Please to comment